Clearance of P16INK4A-POSITIVE senescent cells

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Cancer Institute and 2 more

Animals1

Outcomes

p16(Ink4a)-positive senescent cells

downin mice1

1 study

Clearance of P16INK4A-POSITIVE senescent cells decrease p16(Ink4a)-positive senescent cells in mice.
“INK-ATTAC removes p16(Ink4a)-positive senescent cells upon drug treatment”
Animalsin BubR1 progeroid mice
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Nature2 Nov 2011

More on p16(Ink4a)-positive senescent cells

Age-related diseases

downin mice1

1 study

Clearance of P16INK4A-POSITIVE senescent cells decrease age-related diseases in mice.
“late-life clearance attenuated progression of already established age-related disorders”
Animalsin BubR1 progeroid mice (late-life clearance)
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Nature2 Nov 2011

Latest

Nature2 Nov